Terms: = Brain cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
8 results:
1. treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
Flies CM; Friedrich M; Lohmann P; van Garderen KA; Smits M; Tonn JC; Weller M; Galldiks N; Snijders TJ
Neuro Oncol; 2024 May; 26(5):902-910. PubMed ID: 38219019
[TBL] [Abstract] [Full Text] [Related]
2. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A; Huser J; Schmid S; Schär S; Scherz A; Gautschi O; Mauti L; von Briel T; Waibel C; Wannesson L; Pankovics J; Mark MT; Rothschild SI; Addeo A; Janthur WD; Siano M; Boos L; Britschgi C; Früh M
Lung Cancer; 2024 Jan; 187():107427. PubMed ID: 38043395
[TBL] [Abstract] [Full Text] [Related]
4. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract] [Full Text] [Related]
5. The Change of Soluble Programmed Death Ligand 1 (spd-L1) in Plasma of Small Cell Lung cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract] [Full Text] [Related]
6. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract] [Full Text] [Related]
7. A novel miR-7156-3p-hoxd13 axis modulates glioma progression by regulating tumor cell stemness.
Zhang J; Deng M; Tong H; Xue W; Guo Y; Wang J; Chen L; Wang S
Int J Biol Sci; 2020; 16(16):3200-3209. PubMed ID: 33162825
[TBL] [Abstract] [Full Text] [Related]
8. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
Attanasio R; Montini M; Valota M; Cortesi L; Barbò R; Biroli F; Tonnarelli G; Albizzi M; Testa RM; Pagani G
Pituitary; 2008; 11(1):1-11. PubMed ID: 17690987
[TBL] [Abstract] [Full Text] [Related]
